The fascinating history of the importance of I... - CLL Support
The fascinating history of the importance of IGHV mutation status in CLL prognosis and treatment
You need to be a member of this community to see this post.
Read more about...
- Chemotherapy
- Vaccination
- Immunoglobulin
- Radioactive iodine
- Immunoglobulin M
- Amino acids
- FCR
- Chronic leukaemia
- Targeted therapy
63 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying CLL patients with early treatment requirement
Most of us would be aware of the prognostic value of the immunoglobulin heavy-chain variable region...
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine,...
Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in CLL? - Dr Keating
A complex but interesting read
Acta Haematol August 2018;140:51–54
The immunoglobulin heavy chain...
Mutated and unmutated cll for dummies
When told I had chronic lymphocytic leukemia (cll) four years ago, all I heard was "leukemia"....
Relative risk for secondary bone marrow cancer within 5 years after initial CLL chemoimmunotherapy treatment (typically BR or FCR)
In countries where targeted therapies ('brutinibs, venetoclax, obinutuzumab/rituximab) are now...
Related Posts
Does CLL begin neonatal?- Question - how many different varieties of antibodies can B-cells make? Hint - it's hypermutation (IGHV mutation) that makes it possible
- Potential Early Drivers of Disease in Treatment-Naive CLL Identified
Five-year results for the iFCG regimen: first-line treatment of CLL patients with mutated IGHV and without del(17p)/TP53 mutation- NOTCH1 mutational status - high risk of transformation and poor outcome
